• The Company
    • Who we are
    • Partner Portal
  • Meet the Partners
  • Our Approach
  • Portfolio
    • Current Portfolio
    • Historic Portfolio
  • News
  • Contact Us
The Vertical Group
Investing for Innovation

Innovator CEO profile: Omada Health’s Sean Duffy

5/16/2022

 
Via: Health Evolution
When Sean Duffy co-founded Omada Health in 2011, the pursuit was to reinvent how people manage chronic disease.  

By 2015, Omada earned full recognition from the U.S. Centers for Disease Control & Prevention for company’s digital diabetes prevention program and in 2018 it began a clinical trial demonstrating more than 4% percent average weight loss in a year among users.  

Health Evolution interviewed Duffy about the inspiration behind Omada Health, what perspective clients should expect in the next 18 months, and the most difficult challenge he has overcome as a leader. ​

Read More: ​
https://www.healthevolution.com/insider/innovator-ceo-profile-omada-healths-sean-duffy/

FDA expands indication to standard risk patients for transcarotid stent system

5/3/2022

 
Via: Healio
The FDA approved an expanded indication for a transcarotid stent system to include patients at standard risk for adverse events from carotid endarterectomy, according to a press release from Silk Road Medical.

Previously, the stent system (Enroute) was approved for use only in patients with anatomic or physiological criteria that put them at high risk for complications from more invasive surgical procedures.


“This is the first time in history that a stent-based approach has demonstrated noninferiority in stroke and death rates relative to CEA, with our transcarotid artery revascularization [TCAR] system offering the added benefit of significantly reduced cranial nerve injury risk,” Erica Rogers, president and CEO of Silk Road Medical, said in the release. “This label expansion levels a playing field once dominated by open surgical techniques, allowing an expanded number of patients and physicians access to the benefits of a less invasive treatment option.”

Read More: ​https://www.healio.com/news/cardiac-vascular-intervention/20220503/fda-expands-indication-to-standard-risk-patients-for-transcarotid-stent-system

Silk Road Medical’s Enroute TCAR System Approved for Expanded Indication of Standard-Risk Patients

5/2/2022

 
Via: Endovascular Today
May 2, 2022—Silk Road Medical, Inc. announced that the FDA approved expanded indications for the company’s Enroute stent for transcarotid artery revascularization (TCAR) to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with anatomic or physiologic criteria that put them at high risk of complications from more invasive surgical procedures.

According to Silk Road Medical, the company had previously submitted a premarket approval supplement, which included data extracted from the Vascular Quality Initiative. The surveillance data included in the submission represented real-world outcomes in 20,264 patients considered at standard surgical risk.

Those data demonstrated that use of Silk Road Medical’s TCAR system is statistically noninferior in stroke and death outcomes to CEA, while showing a ninefold reduction in cranial nerve injury (2.7% vs 0.3%; P ≤ .001), reported the company.

Read More: ​https://evtoday.com/news/silk-road-medicals-enroute-tcar-system-approved-for-expanded-indication-of-standard-risk-patients

    Archives

    October 2023
    September 2023
    September 2022
    August 2022
    June 2022
    May 2022
    February 2022
    January 2022
    December 2021
    May 2021
    April 2021
    February 2021
    January 2021
    December 2020
    November 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    December 2019
    November 2019
    October 2019
    August 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    April 2015
    March 2015
    February 2015
    January 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    RSS Feed

© The Vertical Group - [email protected]
 PO 218, Berkeley Heights, NJ 07922 | (908) 277-3737
PO 5006, San Mateo, CA  94402 | (650) 566-9060
Picture
Website by Custom Dynamics